<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ctm270557" xml:lang="en" article-type="letter" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Med</journal-id><journal-id journal-id-type="pmc-domain-id">1991</journal-id><journal-id journal-id-type="pmc-domain">clintransmed</journal-id><journal-id journal-id-type="publisher-id">CTM2</journal-id><journal-title-group><journal-title>Clinical and Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">2001-1326</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12759042</article-id><article-id pub-id-type="pmcid-ver">PMC12759042.1</article-id><article-id pub-id-type="pmcaid">12759042</article-id><article-id pub-id-type="pmcaiid">12759042</article-id><article-id pub-id-type="pmid">41482634</article-id><article-id pub-id-type="doi">10.1002/ctm2.70557</article-id><article-id pub-id-type="publisher-id">CTM270557</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Letter to the Journal</subject></subj-group><subj-group subj-group-type="heading"><subject>Letter to the Journal</subject></subj-group></article-categories><title-group><article-title>Fallopian tube lavage sampling towards early detection of pre&#8208;invasive ovarian cancer</article-title><alt-title alt-title-type="left-running-head">SEATON <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="ctm270557-cr-0001" contrib-type="author"><name name-style="western"><surname>Seaton</surname><given-names initials="M">Melanie</given-names></name><xref rid="ctm270557-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ctm270557-cr-0002" contrib-type="author"><name name-style="western"><surname>Harbach</surname><given-names initials="S">Sarah</given-names></name><xref rid="ctm270557-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270557-note-0001" ref-type="author-notes">
<sup>&amp;</sup>
</xref></contrib><contrib id="ctm270557-cr-0003" contrib-type="author"><name name-style="western"><surname>Oke</surname><given-names initials="J">Joanne</given-names></name><xref rid="ctm270557-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ctm270557-cr-0004" contrib-type="author"><name name-style="western"><surname>Walker</surname><given-names initials="TDJ">Thomas D. J.</given-names></name><xref rid="ctm270557-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ctm270557-cr-0005" contrib-type="author"><name name-style="western"><surname>Dalton&#8208;O'Reilly</surname><given-names initials="J">Jessica</given-names></name><xref rid="ctm270557-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270557-note-0001" ref-type="author-notes">
<sup>&amp;</sup>
</xref></contrib><contrib id="ctm270557-cr-0006" contrib-type="author"><name name-style="western"><surname>Selley</surname><given-names initials="J">Julian</given-names></name><xref rid="ctm270557-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ctm270557-cr-0007" contrib-type="author"><name name-style="western"><surname>Brison</surname><given-names initials="DR">Daniel R.</given-names></name><xref rid="ctm270557-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ctm270557-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ctm270557-cr-0008" contrib-type="author"><name name-style="western"><surname>Bolton</surname><given-names initials="J">James</given-names></name><xref rid="ctm270557-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270557-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ctm270557-cr-0009" contrib-type="author"><name name-style="western"><surname>Meyer</surname><given-names initials="S">Stefan</given-names></name><xref rid="ctm270557-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270557-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="ctm270557-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ctm270557-cr-0010" contrib-type="author"><name name-style="western"><surname>Knight</surname><given-names initials="D">David</given-names></name><xref rid="ctm270557-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ctm270557-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Edmondson</surname><given-names initials="RJ">Richard J.</given-names></name><xref rid="ctm270557-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270557-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270557-aff-0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="ctm270557-note-0001" ref-type="author-notes">
<sup>&amp;</sup>
</xref><address><email>richard.edmondson@manchester.ac.uk</email></address></contrib><contrib id="ctm270557-cr-0012" contrib-type="author" corresp="yes"><name name-style="western"><surname>Schmidt</surname><given-names initials="CK">Christine K.</given-names></name><xref rid="ctm270557-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270557-note-0001" ref-type="author-notes">
<sup>&amp;</sup>
</xref><address><email>christine.schmidt@manchester.ac.uk</email></address></contrib></contrib-group><aff id="ctm270557-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Manchester Cancer Research Centre</named-content>
<named-content content-type="organisation-division">Division of Cancer Sciences</named-content>
<named-content content-type="organisation-division">Faculty of Biology</named-content>
<named-content content-type="organisation-division">School of Medical Sciences</named-content>
<named-content content-type="organisation-division">Medicine and Health</named-content>
<institution>University of Manchester</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Gynaecological Oncology</named-content>
<named-content content-type="organisation-division">Division of Cancer Sciences</named-content>
<named-content content-type="organisation-division">Faculty of Biology</named-content>
<named-content content-type="organisation-division">School of Medical Sciences</named-content>
<named-content content-type="organisation-division">Medicine and Health</named-content>
<institution>University of Manchester</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Biological Mass Spectrometry Core Facility</named-content>
<named-content content-type="organisation-division">Faculty of Biology</named-content>
<named-content content-type="organisation-division">Medicine and Health</named-content>
<named-content content-type="organisation-division">Manchester Academic Health</named-content>
<named-content content-type="organisation-division">Science Centre</named-content>
<institution>University of Manchester</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Maternal and Fetal Health Research Centre</named-content>
<named-content content-type="organisation-division">Division of Developmental Biology and Medicine</named-content>
<named-content content-type="organisation-division">Faculty of Biology</named-content>
<named-content content-type="organisation-division">Medicine and Health</named-content>
<named-content content-type="organisation-division">School of Medical Sciences</named-content>
<institution>University of Manchester</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Reproductive Medicine</named-content>
<named-content content-type="organisation-division">St Mary's Hospital, Manchester University NHS Foundation Trust</named-content>
<institution>Manchester Academic Health Sciences Centre</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<named-content content-type="organisation-division">Manchester University NHS Foundation Trust</named-content>
<institution>Manchester Academic Health Science Centre</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Paediatric Haematology and Oncology</named-content>
<institution>Royal Manchester Children's Hospital</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Young Oncology Unit</named-content>
<institution>The Christie NHS Foundation Trust</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="ctm270557-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">St Mary's Hospital</named-content>
<named-content content-type="organisation-division">Central Manchester</named-content>
<named-content content-type="organisation-division">NHS Foundation Trust</named-content>
<institution>Manchester Academic Health Science Centre</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Richard J. Edmondson and Christine K. Schmidt, Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UK.<break/> Email: <email>richard.edmondson@manchester.ac.uk</email>; <email>christine.schmidt@manchester.ac.uk</email><break/></corresp><fn id="ctm270557-note-0001"><label>&amp;</label><p>For the NEMO Consortium (International Alliance for Cancer Early Detection &#8211; ACED).</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>16</volume><issue seq="100">1</issue><issue-id pub-id-type="pmc-issue-id">503227</issue-id><issue-id pub-id-type="doi">10.1002/ctm2.v16.1</issue-id><elocation-id>e70557</elocation-id><history><date date-type="rev-recd"><day>26</day><month>11</month><year>2025</year></date><date date-type="received"><day>14</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>04</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-04 07:25:14.947"><day>04</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2026 The Author(s). <italic toggle="yes">Clinical and Translational Medicine</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CTM2-16-e70557.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CTM2-16-e70557.pdf"/><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Cancer Research UK</institution><institution-id institution-id-type="doi">10.13039/501100000289</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Biotechnology and Biological Sciences Research Council</institution><institution-id institution-id-type="doi">10.13039/501100000268</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="9"/><word-count count="3080"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:03.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="ctm270557-note-0002" fn-type="equal"><p>Melanie Seaton and Sarah Harbach contributed equally to this work. Richard J. Edmondson and Christine K. Schmidt contributed equally to this work.</p></fn></fn-group></notes></front><body><sec sec-type="opening-section" id="ctm270557-sec-0010"><label>1</label><p>Dear Editor,</p><p>Most high&#8208;grade serous ovarian cancer (HGSOC) cases arise from pre&#8208;invasive fallopian tube (FT) lesions, known as serous tubal intraepithelial carcinomas (STICs). Yet, despite an estimated 6&#8208; to 7&#8208;year window&#8208;of&#8208;opportunity, no clinical test exists for detecting these at an early, treatable stage.<xref rid="ctm270557-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> To address this, we developed and applied a novel sampling technique to obtain FT lavage, enabling analysis of early tumour&#8208;associated molecular changes in FT&#8208;derived biofluids.</p><p>To establish the feasibility of this technique, we collected 27 FT lavages from high&#8208;risk <italic toggle="yes">BRCA1/2</italic> mutation carriers, ovarian neoplasm (ON) patients, and control individuals with benign or non&#8208;tubal gynaecological conditions (Figure&#160;<xref rid="ctm270557-fig-0001" ref-type="fig">1A</xref> and&#160;<xref rid="ctm270557-fig-0001" ref-type="fig">B</xref>; Supplementary Discussions 1 and 2). Lavages were acquired from FTs directly after surgical removal by inserting a PBS&#8208;filled syringe into the FT lumen beyond the fimbrial end and flushing towards the utero&#8208;tubal junction (Figure&#160;<xref rid="ctm270557-fig-0002" ref-type="fig">2A</xref>). Sampling away from the fimbriae enabled us to test for signals diffusing from any lesions proximally along the tube, where they would be accessible via minimally invasive trans&#8208;cervical falloposcopy,<xref rid="ctm270557-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> supporting potential clinical feasibility (Supplementary Discussion 3).</p><fig position="float" fig-type="FIGURE" id="ctm270557-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Patient stratification and clinical information of sampled fallopian tube lavages. (A) Schematic, illustrating the different patient groups from whom fallopian tube (FT) lavage samples were collected: women having surgery for cervical cancer, squamous cell carcinoma (SCC) or benign ovarian fibroma without ovarian cancer or known mutations in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic> or other homologous recombination genes (group 1: low&#8208;risk/controls; blue), women at high risk of developing ovarian cancer (groups 2/3: <italic toggle="yes">BRCA1/2</italic>&#8208;mutation carriers; salmon/orange), patients diagnosed with an ovarian neoplasm, with affected (group 4: green) and unaffected (group 5: purple) FTs. Created with BioRender.com. (B) Patient characteristics and clinical information for FT lavage samples used in the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CTM2-16-e70557-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ctm270557-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Candidate protein signatures delineating fallopian tube lavages of high&#8208;risk/ovarian neoplasm patients. (A) Schematic illustrating the collection and processing steps of fallopian tube (FT) samples for analysis, including their concentration, depletion of common blood proteins and S&#8208;trap column digestion before analysis by liquid chromatography mass spectrometry (LC&#8208;MS). FT lavage samples were obtained by inserting a syringe containing PBS into the fimbrial end, with the syringe tip positioned just beyond the fimbrial ostium within the tubal lumen. Sterile PBS was gently introduced, without applying pressure, towards the utero&#8208;tubal junction, and the resulting fluid was collected for downstream analysis. Created using BioRender.com. (B) Dot plot depicting the correlation of detected proteins obtained for the left and right tube of a patient diagnosed with a unilateral ovarian neoplasm (MFC6, see Figure&#160;<xref rid="ctm270557-fig-0001" ref-type="fig">1B</xref> for patient information). Proteins of interest, notably more abundant in the neoplasm or unaffected tube, are highlighted in green and pink, respectively. Note that the comparison is based on <italic toggle="yes">n</italic>&#160;=&#160;1 patient with no statistical significance implied. (C) Flow chart showing analytical pipeline from raw data through to altered protein signatures. After removal of blood proteins from raw data, protein abundances were compared between different risk groups/ovarian neoplasm patients, which identified 82 over&#8208;represented proteins in <italic toggle="yes">BRCA</italic>&#8208;mutation carriers and ovarian neoplasm patients. (D) Plot highlighting the 82 proteins overrepresented in high&#8208;risk/ovarian neoplasm FT lavages compared to controls. Colour&#8208;coding indicates association of proteins with the female reproductive tract (identified using STRING, blue circles), proteins with literature backing as OC biomarker candidates or overexpressed in OC context (yellow circles, black outline), or both (yellow circles, red outline). Note the large number of identified candidates showing tissue&#8208;of&#8208;origin relevance and/or involvement in ovarian cancer&#8208;related pathways, underscoring the biological plausibility of the observed changes; the threshold of 2 is indicated as a blue dotted line. FT: fallopian tube; HGSOC: high&#8208;grade serous ovarian cancer; LC&#8208;MS: liquid chromatography&#8208;mass spectrometry; OC: ovarian cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CTM2-16-e70557-g004.jpg"/></fig><p>As FTs were flushed post&#8208;surgical removal, effects of blood contamination on downstream analysis were reduced through selective depletion of common blood proteins during sample preparation (Figure&#160;<xref rid="ctm270557-fig-0002" ref-type="fig">2A</xref>), and removal of abundant plasma proteins during analysis (Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S1</xref>). Proteomic analysis revealed&#160;&gt; 2000 proteins per sample with significant overlap between samples (Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S1a and b</xref>, Table <xref rid="ctm270557-supinfo-0001" ref-type="">S1</xref>), including FT&#8208;resident mucins (MUC16/CA125, MUC5B, MUC5AC) and oviduct&#8208;specific glycoprotein 1 (OVGP1). No major differences in the numbers of the top 400 plasma proteins detected were identified between samples (mean&#160;&#177;&#160;SD&#160;=&#160;316&#160;&#177;&#160;13.2), and this was proportionally slight (8.7%) compared to overall protein numbers (Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S1a</xref>). Intra&#8208;patient comparison showed strong correlation between left and right FT samples for most pairs (<italic toggle="yes">R</italic>
<sup>2&#160;</sup>&gt;0.9, Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S2a&#8211;d</xref>), overall indicating FT lavage as a promising resource for comparative proteomic analysis across risk and disease states.</p><p>To assess the ability of FT lavage to distinguish between neoplastic and non&#8208;neoplastic samples, we compared proteomes of a left and right FT lavage from a patient with a unilateral ovarian neoplasm (MFC6), thereby controlling for inter&#8208;patient variability and confounding factors. Despite high overall correlation (<italic toggle="yes">R</italic>
<sup>2&#160;</sup>=&#160;0.9933), several tumour&#8208;promoting proteins were enriched in the neoplasm&#8208;associated FT, such as SPTAN1, which is overexpressed in early OC lesions in the FT,<xref rid="ctm270557-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> while tumour suppressor fructose&#8208;1,6&#8208;bisphosphatase 1 (FBP1)<xref rid="ctm270557-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> was reduced (Figure&#160;<xref rid="ctm270557-fig-0002" ref-type="fig">2B</xref>, Table <xref rid="ctm270557-supinfo-0001" ref-type="">S2</xref>), suggesting that our workflow has potential to identify proteins in FT lavage linked to tumour progression and local neoplastic changes.</p><p>We next hypothesised that a subset of the high&#8208;risk group may already exhibit early molecular changes associated with disease progression, detectable by comparison to cancer&#8208;associated FT profiles. We therefore compared FT lavage proteomes from high&#8208;risk and ovarian neoplasm groups to low&#8208;risk controls (Figure&#160;<xref rid="ctm270557-fig-0002" ref-type="fig">2C</xref>). Supporting our hypothesis, 82 proteins were commonly elevated&#160;more than or equal to&#160;twofold across the <italic toggle="yes">BRCA1</italic>/<italic toggle="yes">2</italic>&#8208;mutated and ovarian neoplasm groups over controls (Figure&#160;<xref rid="ctm270557-fig-0002" ref-type="fig">2D</xref>, Tables <xref rid="ctm270557-supinfo-0001" ref-type="">S1</xref> and <xref rid="ctm270557-supinfo-0001" ref-type="">S2</xref>). A marked proportion were representative of the female reproductive system and, in addition to identifying proteins not previously associated with OC, we detected others with established roles in OC progression, metastasis, and prognosis (Figure&#160;<xref rid="ctm270557-fig-0002" ref-type="fig">2D</xref>, Table <xref rid="ctm270557-supinfo-0001" ref-type="">S2</xref>). Key proteins included PTGFRN, detected more frequently in plasma from OC patients than controls,<xref rid="ctm270557-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> ITGA6, linked to increased proliferation and metastasis of OC cells,<xref rid="ctm270557-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> and ZBP1, a reported necroptosis mediator in OC<xref rid="ctm270557-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> with overexpression of its enhancer regions in <italic toggle="yes">BRCA1</italic>&#8208;mutated cells, consistent with ZBP1 enrichment in our <italic toggle="yes">BRCA</italic>&#8208;mutant FT lavages.<xref rid="ctm270557-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Notably, several proposed biomarkers for advanced disease stages and OC drug targets were detected, highlighting potential relevance to early detection. Cellular component enrichment highlighted extracellular and cell membrane proteins as predominant gene ontologies, alongside extracellular vesicles (Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S3a</xref>), suggesting increased secretory activity as a potential source of these proteins.</p><p>Functional protein network and clustering analysis revealed networks associated with actin, apoptosis, cilia, and signalling (Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S3b</xref>). A central EGFR cluster linked to ITGA6, EPCAM and others involved in cancer pathways, including MAPK and PI3K&#8208;AKT (Table <xref rid="ctm270557-supinfo-0001" ref-type="">S2</xref>). Other clusters included proteins linked to carcinogenesis and the FT epithelium. Hierarchical clustering of the different risk/ovarian neoplasm groups revealed that <italic toggle="yes">BRCA1/2</italic>&#8208;mutated groups showed similar protein profiles (Figure <xref rid="ctm270557-supinfo-0001" ref-type="">S3c</xref>). Additionally, controls clustered closely with unaffected FTs from women with unilateral tumours. Notably, the latter were not used to define the protein signature, underscoring our approach's potential for cancer early detection.</p><p>Further hierarchical clustering of individual lavages revealed two main clusters, with marked separation of control and most <italic toggle="yes">BRCA</italic>&#8208;mutated samples from ovarian neoplasms, reflecting expected molecular similarity between average and most high&#8208;risk FTs (Figure&#160;<xref rid="ctm270557-fig-0003" ref-type="fig">3A</xref>). However, in one <italic toggle="yes">BRCA1</italic>&#8208;mutated individual, lavages from their FTs clustered separately, with <italic toggle="yes">BRCA1_2</italic> clustering more closely with an HGSOC sample (Figure&#160;<xref rid="ctm270557-fig-0003" ref-type="fig">3A</xref>). To determine whether this aberrant molecular profile correlated with histological changes, we examined further H&amp;E sections from the FFPE blocks of the fimbrial ends of both FTs. This revealed a STIC lesion in one FT with typical morphology, aberrant p53 expression and increased Ki67 proliferation index on immunohistochemistry&#160;(Figure&#160;<xref rid="ctm270557-fig-0003" ref-type="fig">3B</xref>). The lesion had been previously undetected on initial standard sectioning and by entirely sampling the fimbrial ends according to the SEE&#8208;FIM protocol. Although one instance is not sufficient for firm conclusions, considering the rarity of further STIC lesion detection upon deeper sectioning,<xref rid="ctm270557-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> this is unlikely to be by chance (Supplementary Discussion 4).</p><fig position="float" fig-type="FIGURE" id="ctm270557-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Hierarchical clustering of 82&#8208;protein candidate signature for individual patients and retrospective identification of an incidental STIC. (A) Heatmap and hierarchical clustering of 82 overrepresented proteins for individual fallopian tube (FT) lavages from control (CTRL1&#8208;9), high&#8208;risk (<italic toggle="yes">BRCA1_1&#8208;6</italic>, <italic toggle="yes">BRCA2_1&#8208;6</italic>) and ovarian neoplasm (ON) patients (ON1&#8208;4). Note divergent clustering of patient MFC4's two FT samples (<italic toggle="yes">BRCA1_1&#8208;2</italic>, highlighted in bold), with one of the samples (BRCA1&#8208;2) clustering together with an ovarian neoplasm sample (ON1) in a separate cluster, highlighted in pink. Schematic generated using Morpheus (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://software.broadinstitute.org/morpheus" ext-link-type="uri">https://software.broadinstitute.org/morpheus</ext-link>), with row&#8208;scaled abundances indicated. (B) Previously unidentified serous tubal intraepithelial carcinoma (STIC) in an FT from <italic toggle="yes">BRCA1</italic> patient MFC4 (top panels) compared to normal FT epithelium in opposing FT (bottom panels). Three consecutive 4&#160;&#181;m sections were taken from formalin&#8208;fixed paraffin&#8208;embedded (FFPE) blocks previously processed with the sectioning and extensively examining the fimbriated end (SEE&#8208;FIM) protocol, stained with H&amp;E, or for p53 or Ki67. Scale bars indicate 100&#160;&#181;m (left column) or 50&#160;&#181;m for insets (right column). FFPE: formalin&#8208;fixed paraffin&#8208;embedded; FT: fallopian tube; SEE&#8208;FIM: sectioning and extensively examining the fimbrial end; STIC: serous tubal intraepithelial carcinoma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CTM2-16-e70557-g003.jpg"/></fig><p>To validate our findings and further determine their relevance to STIC identification, we performed immunofluorescence staining of five STIC lesions from an independent cohort of three patients (Figure&#160;<xref rid="ctm270557-fig-0004" ref-type="fig">4A and B</xref>). ITGA6, EGFR and EPCAM were chosen from our 82&#8208;protein candidate signature for their centrality to our STRING network and predicted surface presence for future therapeutic targeting. ITGA6 showed consistent increased staining in STICs compared to neighbouring healthy FT epithelium (FTE), while EPCAM exhibited less pronounced alterations (Figure&#160;<xref rid="ctm270557-fig-0004" ref-type="fig">4B and C</xref>). Despite variation in EGFR intensity differences, strong apical staining in healthy FTE contrasted with diffuse staining in STICs (Figure&#160;<xref rid="ctm270557-fig-0004" ref-type="fig">4D and E</xref>), reflecting polarity loss<xref rid="ctm270557-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> and suggesting distinct mechanisms of protein accumulation in FT fluid.</p><fig position="float" fig-type="FIGURE" id="ctm270557-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Candidate protein changes in STIC lesions from an independent patient cohort. (A) Patient characteristics and clinical information for STIC lesion&#8208;containing fallopian tube (FT) tissue sections used in this study. Number of STICs indicates lesions analysed by immunofluorescence (IF)/immunohistochemistry (IHC). (B) IHC and IF staining of representative STIC lesions. Left panels show the characteristic H&amp;E (left) and p53 (right) staining of a STIC lesion from patient <bold>P1</bold> (see (a) for patient information). Right panels depict IF staining of consecutive sections from the same formalin&#8208;fixed paraffin&#8208;embedded (FFPE) block for ITGA6 (left), EPCAM (middle) and EGFR (right), showing levels of the key proteins identified as overrepresented in high&#8208;risk/ovarian neoplasm groups in a STIC lesion compared to the surrounding normal&#8208;appearing FT epithelium (FTE). For EGFR, the concentrated staining at the apical membrane of normal&#8208;appearing epithelium is lost in the STIC lesion (see insets). Scale bars indicate 100&#160;&#181;m, or 20&#160;&#181;m for EGFR insets. (C) Quantification of median IF staining intensities of ITGA6 and EPCAM measured across multiple regions of the STIC lesion featured in (B) and adjacent normal&#8208;appearing FTE for two lesions for patients P1 and P2 and one lesion for patient P3 (see (A) for patient specifics).&#160;&gt;300 points were analysed per STIC/adjacent normal FT epithelium (FTE), corrected for background and normalised to the average normal FTE fluorescence. Median fluorescence intensities were calculated for normal FTE and STIC lesions per lesion (<italic toggle="yes">n</italic>&#160;=&#160;5). Statistical significance was determined using one&#8208;tailed Wilcoxon matched&#8208;pairs signed rank testing. (D) Quantification of EGFR IF in one representative lesion from patient P1 shown in (B), measured across five regions from the apical to basal axis of the STIC lesion, and across five regions of the surrounding normal&#8208;appearing FTE. Average fluorescence intensity is plotted (solid blue/orange lines) with standard deviation indicated (dotted blue/orange lines with shading). Apical and basal regions for normal FTE and STIC lesions, alongside disordered region in STIC lesions are indicated. (E) Quantification of EGFR IF shown in (B) along multiple regions of the basal and apical membranes of the STIC lesion and normal&#8208;appearing surrounding FTE. Two STICs were analysed for patient P1, and one STIC for patients P2 and P3 (see (A) for patient information).&#160;&gt;300 points were analysed per STIC/adjacent normal FTE for both apical and basal membranes, corrected for background and normalised to the average normal FTE basal fluorescence. Median fluorescence intensities were calculated for apical and basal regions across normal FTE and STIC lesions; statistical significance was determined with a one&#8208;tailed Wilcoxon matched&#8208;pairs signed rank test. AU: arbitrary units; BRCA: breast cancer susceptibility gene; EPCAM: epithelial cell adhesion molecule; EGFR: epidermal growth factor receptor; FFPE: formalin&#8208;fixed paraffin&#8208;embedded; FT: fallopian tube; FTE: fallopian tube epithelium, H&amp;E: haematoxylin &amp; eosin; IF: immunofluorescence; IHC: immunohistochemistry; ITGA6: integrin alpha&#8208;6; STIC: serous tubal intraepithelial carcinoma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="CTM2-16-e70557-g002.jpg"/></fig><p>In conclusion, we have identified a candidate signature present in the lavage of FTs which enabled retrospective identification of a STIC lesion in a high&#8208;risk <italic toggle="yes">BRCA</italic> mutation carrier. While further exploration and validation in larger cohorts is needed (Supplementary Discussion 5), our findings point to a promising direction for less invasive OC risk management strategies that could help delay or eliminate the need for invasive prophylactic surgeries while preserving fertility in high&#8208;risk women.</p></sec><sec id="ctm270557-sec-0020"><title>AUTHOR CONTRIBUTIONS</title><p>The project was conceived and supervised by CKS and RJE. MS and SH carried out the experiments and performed data analysis and interpretation, with support from JO, TDJW and JDO'R. JS and DK conducted the mass spectrometry workflows. JB provided pathological expertise and performed retrospective STIC assessments. SM and DRB contributed critical insights into relevant clinical contexts. All authors reviewed and discussed the findings and provided feedback on the manuscript.</p></sec><sec id="ctm270557-sec-0040"><title>FUNDING</title><p>The authors acknowledge funding by a BBSRC David Phillips Fellowship (BB/N019997/1 to CKS), an MRC research grant (MR/X008754/1 to CKS), a CRUK International Alliance for Cancer Early Detection (ACED) programme grant (Novel Early Markers for Ovarian cancer (NEMO) &#8211; ACEPGM&#8208;2023/100001), a Manchester Academic Health Science Centre Women's and Children's Domain Advanced Technologies Pump&#8208;Priming Award, as well as MCRC/CRUK and CRUK MB PhD studentships to MS and JO.</p></sec><sec sec-type="COI-statement" id="ctm270557-sec-0050"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest.</p></sec><sec id="ctm270557-sec-0080"><title>ETHICS STATEMENT</title><p>Fallopian tube lavages and formalin&#8208;fixed paraffin&#8208;embedded fallopian tube tissues were obtained via the Manchester University NHS Foundation Trust (MFT) Biobank under Human Tissue Authority (HTA)&#8208;approved ethics applications (REC14/NW/1260 and REC19/NW/0644). All patients provided their written informed consent and were prospectively included in the study.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ctm270557-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="ctm270557-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTM2-16-e70557-s005.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ctm270557-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTM2-16-e70557-s004.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ctm270557-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTM2-16-e70557-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ctm270557-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTM2-16-e70557-s001.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ctm270557-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTM2-16-e70557-s003.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ctm270557-sec-0030"><title>ACKNOWLEDGEMENTS</title><p>We thank the patients who participated in our study for their generous help, time and selflessness in donating their samples. We extend our gratitude to Jay Brown for supporting patient recruitment, data acquisition and management, and securing regulatory approvals. We thank Amy Hawarden, Katie Baxter, Caitlin Waddell, Emma Mullen and Marcus Price for in&#8208;theatre assistance with FT lavage collection and the BioMS team for sample preparation. We are grateful to Gary Ashton and Steve Bagley of the CRUK&#8208;MI as well as their teams, particularly Caron Behan, for help with immunohistochemistry, immunofluorescence and microscopy procedures.</p></ack><sec sec-type="data-availability" id="ctm270557-sec-0070"><title>DATA AVAILABILITY STATEMENT</title><p>Details of the approaches and techniques used are outlined in the Supplementary Methods section. Fallopian tube lavage mass spectrometry proteomics data are available in Table <xref rid="ctm270557-supinfo-0001" ref-type="">S1</xref>. The raw data are accessible through the PRIDE repository (accession number: PXD072299).</p></sec><ref-list id="ctm270557-bibl-0001"><title>REFERENCES</title><ref id="ctm270557-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ctm270557-cite-0002"><string-name name-style="western"><surname>Labidi&#8208;Galy</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Papp</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hallberg</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>High grade serous ovarian carcinomas originate in the fallopian tube</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-017-00962-1</pub-id><pub-id pub-id-type="pmid">29061967</pub-id><pub-id pub-id-type="pmcid">PMC5653668</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ctm270557-cite-0003"><string-name name-style="western"><surname>Rocha</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Drake</surname><given-names>WK</given-names></string-name>, et&#160;al. <article-title>First clinical feasibility and safety study of a novel multimodality fallopian tube imaging endoscope</article-title>. <source>Lasers Surg Med</source> Published online <year>2025</year>:<fpage>163</fpage>&#8208;<lpage>170</lpage>. doi:<pub-id pub-id-type="doi">10.1002/lsm.23877</pub-id><pub-id pub-id-type="pmid">39789754</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ctm270557-cite-0004"><string-name name-style="western"><surname>Wisztorski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aboulouard</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Roussel</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Fallopian tube lesions as potential precursors of early ovarian cancer: a comprehensive proteomic analysis</article-title>. <source>Cell Death Dis</source>. <year>2023</year>;<volume>14</volume>(<issue>9</issue>). doi:<pub-id pub-id-type="doi">10.1038/s41419-023-06165-5</pub-id><pub-id pub-id-type="pmcid">PMC10541450</pub-id><pub-id pub-id-type="pmid">37775701</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ctm270557-cite-0005"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C&#8208;MYC/STAT3 signaling axis in ovarian cancer</article-title>. <source>Oncogene</source>. <year>2021</year>;<volume>40</volume>(<issue>40</issue>):<fpage>5938</fpage>&#8208;<lpage>5949</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41388-021-01957-5</pub-id><pub-id pub-id-type="pmid">34363022</pub-id><pub-id pub-id-type="pmcid">PMC8497274</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ctm270557-cite-0006"><string-name name-style="western"><surname>Dufresne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bowden</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Thavarajah</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>The plasma peptides of ovarian cancer</article-title>. <source>Clin Proteomics</source>. <year>2018</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12014-018-9215-z</pub-id><pub-id pub-id-type="pmid">30598658</pub-id><pub-id pub-id-type="pmcid">PMC6302491</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ctm270557-cite-0007"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>. <article-title>Long non&#8208;coding RNA OIP5&#8208;AS1 suppresses microRNA&#8208;92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6</article-title>. <source>J Ovarian Res</source>. <year>2022</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13048-021-00937-3</pub-id><pub-id pub-id-type="pmid">35168644</pub-id><pub-id pub-id-type="pmcid">PMC8848981</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ctm270557-cite-0008"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>S</given-names></string-name>. <article-title>Fisetin&#8208;induced cell death in human ovarian cancer cell lines via zbp1&#8208;mediated necroptosis</article-title>. <source>J Ovarian Res</source>. <year>2022</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13048-022-00984-4</pub-id><pub-id pub-id-type="pmid">35538559</pub-id><pub-id pub-id-type="pmcid">PMC9092675</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ctm270557-cite-0009"><string-name name-style="western"><surname>Bruand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barras</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mina</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Cell&#8208;autonomous inflammation of BRCA1&#8208;deficient ovarian cancers drives both tumor&#8208;intrinsic immunoreactivity and immune resistance via STING</article-title>. <source>Cell Rep</source>. <year>2021</year>;<volume>36</volume>(<issue>3</issue>). doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2021.109412</pub-id><pub-id pub-id-type="pmcid">PMC8371260</pub-id><pub-id pub-id-type="pmid">34289354</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ctm270557-cite-0010"><string-name name-style="western"><surname>Rabban</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Krasik</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Crawford</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zaloudek</surname><given-names>CJ</given-names></string-name>. <article-title>Multistep level sections to detect occult fallopian tube carcinoma in risk&#8208;reducing salpingo&#8208;oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol</article-title>. <source>Am J Surg Pathol</source>. <year>2009</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1878</fpage>&#8208;<lpage>1885</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PAS.0b013e3181bc6059</pub-id><pub-id pub-id-type="pmid">19898224</pub-id></mixed-citation></ref><ref id="ctm270557-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ctm270557-cite-0011"><string-name name-style="western"><surname>Vang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shih</surname><given-names>IM</given-names></string-name>. <article-title>Serous tubal intra&#8208;epithelial carcinoma: what do we really know at this point?</article-title>. <source>Histopathology</source>. <year>2022</year>;<volume>81</volume>(<issue>5</issue>):<fpage>542</fpage>&#8208;<lpage>555</lpage>. doi:<pub-id pub-id-type="doi">10.1111/his.14722</pub-id><pub-id pub-id-type="pmid">35859323</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>